Chemotherapy selection pressure alters sphingolipid composition and mitochondrial bioenergetics in resistant HL-60 cells.
Kao, Li-Pin; Morad, Samy A F; Davis, Traci S; MacDougall, Matthew R; Kassai, Miki; Abdelmageed, Noha; Fox, Todd E; Kester, Mark; Loughran, Thomas P; Abad, Jose' L; Fabrias, Gemma; Tan, Su-Fern; Feith, David J; Claxton, David F; Spiegel, Sarah; Fisher-Wellman, Kelsey H; Cabot, Myles C.
J Lipid Res
; 60(9): 1590-1602, 2019 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-31363040
Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing.
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.
FF-10502, an Antimetabolite with Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer Cells.
Combination of guanine arabinoside and Bcl-2 inhibitor YC137 overcomes the cytarabine resistance in HL-60 leukemia cell line.
Superresolution imaging of individual replication forks reveals unexpected prodrug resistance mechanism.
Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation.
Scavenger receptor class BI (SR-BI) mediates uptake of CPX-351 into K562 leukemia cells.
An Integrated Genome-wide CRISPRa Approach to Functionalize lncRNAs in Drug Resistance.
Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2.
Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes.